USPT

US-PAT-NO: 5270030 DOCUMENT-IDENTIFIER: US 5270030 A TITLE: Fibrin binding domain polypeptide and method of producing DATE-ISSUED: December 14, 1993 INVENTOR-INFORMATION: CITY STATE ZIP CODE NAME COUNTRY Vogel; Tikva Rehovot N/A N/A ILX N/A N/A Levanon; Avigdor Rehovot ILX N/A N/A Werber; Moshe M. Tel Aviv ILX N/A N/A Guy; Rachel Rehovot ILX N/AN/A Panet; Amos Jerusalem ILX ASSIGNEE INFORMATION: ZIP CODE NAME CITY STATE COUNTRY TYPE CODE Bio-Technology General New York NY N/A N/A 02 Corp. 7/ 526397 APPL-NO: DATE FILED: May 21, 1990 PARENT-CASE: This application is a continuation-in-part of U.S. Ser. 345,952, filed Apr. 28, 1989, now abandoned, which is a continuation-in-part of U.S. Ser. No. 291,951, filed Dec. 29, 1988, now abandoned, the contents of both of which are hereby incorporated by reference into this application. FOREIGN-APPL-PRIORITY-DATA: FOREIGN-PRIORITY: FOREIGN-PRIORITY-APPL-NO: CA 2006929 FOREIGN-PRIORITY-APPL-DATE: December 29, 1989 INT-CL: [5] A61K099/00,C07K013/00 ,C12N015/74 ,C12P021/02 US-CL-ISSUED: 424/9,530/350 ,530/395 ,435/320.1 ,435/69.1 ,435/252.3 ,435/252.33 ,435/240.1 ,424/1.1 US-CL-CURRENT: 424/1.69,424/9.341 ,424/9.4 ,435/252.3 ,435/252.33 ,435/320.1 ,435/69.1 ,530/350 ,530/395 FIELD-OF-SEARCH: 530/350;530/395;435/320.1;435/69.1;435/252.3 ;435/252.33 ;435/240.1 ;424/9 ;424/1.1 ;534/10 ;436/173 ;128/653.4

REF-CITED:

	REF-CITED:							
	PAT-NO 4315906 4455290 4587122 4663146 4839464	ISSUE-DA February 1982 June 1984 May 1986 May 1987 June 1989	ATE PATE 2 Gelder Olexa et Kagitani	et al. al.	US-CL 424/1 424/1.1 424/101 424/1.1 530/326			
	COUNTRY US-CL		FOREIGN PATENT FOREIGN-PAT-NO		\TE			
	EP 530/350		0207751	January	1987			
	JP WO		1261398 WO89/00051	October January				
	ART-UNIT:	182						
		AMINER: Ossa -FIRM: White;						
	This invention provides an imaging agent which comprises a polypeptide							
		abeled with an imageable marker, such polypeptide having an						
	sequence si	quence substantially present in the fibrin binding domain of turally-occurring human fibronectin and being capable of						
	binding to	ing to fibrin. invention further provides a method wherein the imaging agent						
is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plague. Further provided are plasmids for expression of								
								polypeptide
	domain of	_	an fibronectin					
	binding to	fibrin,	olasmids, metho					
	polypeptide	es, methods	polypeptides, a	_				
	refolding a	and						
	purified							
	origin which	polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin						
	binding do	main of						
	naturally-obinding to fibrin.	-	an fibronectin	and which are	capable of			

Case 19 Pofile

15 Claims, 62 Drawing figures

CLAIMS:

What is claimed is:

- 1. An imaging agent which comprises a polypeptide labeled with an imageable marker, wherein the polypeptide is a 12 kD polypeptide corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin and having the amino acid sequence of amino acids 1-109 as shown in FIG. 1 and being capable of binding to fibrin.
- 2. A composition comprising an effective imaging amount of the imaging agent of claim 1 and a physiologically acceptable carrier.
- 3. An agent of claim 1, wherein the marker is a radioactive isotope, an element which is opaque to X-rays, or a paramagnetic ion.
- 4. An agent of claim 3, wherein the marker is a radioactive isotope.
- 5. An agent of claim 4, wherein the radioactive isotope is indium-111.
- 6. An agent of claim 4, wherein the radioactive isotope is technetium-99m.
- 7. An agent of claim 4, wherein the radioactive isotope is iodine-123, iodine-131, krypton-81m, xenon-133, or gallium-67.
- 8. A purified polypeptide substantially free of other substances of human origin wherein the polypeptide is a 12 kD polypeptide of amino acids 1-109 as

shown in FIG. 1 corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin.

- 9. A plasmid for expression of the polypeptide of claim 8 comprising DNA encoding the polypeptide and DNA encoding suitable regulatory elements positioned relative to the DNA encoding the polypeptide so as to effect expression of the polypeptide in a suitable host cell.
- 10. A plasmid according to claim 9 designated pFN 196-2 and deposited in escherichia coli strain A4255 under ATCC Accession No. 63328.
- 11. A cell which comprises the plasmid of claim 9.
- 12. A bacterial cell according to claim 11.
- 13. An Escherichia coli cell according to claim 12.
- 14. An Escherichia coli cell according to claim 13, wherein the plasmid is designated pFN 196-2 and wherein the cell is deposited under ATCC Acession No. 68328.
- 15. A method of producing a 12 kD polypeptide fragment corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin which comprises culturing a cell according to claim 11 so that the DNA directs expression of the polypeptide and the cell expressed the polypeptide and recovering from the cell the polypeptide so expressed.

USPT

```
US-PAT-NO: 5455158
DOCUMENT-IDENTIFIER: US 5455158 A
TITLE: Fibrin binding domain polypeptides and uses and methods
of producing
same
DATE-ISSUED: October 3, 1995
INVENTOR-INFORMATION:
NAME
                         CITY
                                            STATE
                                                      ZIP CODE
COUNTRY
                                            N/A
                                                      N/A
Vogel; Tikva
                        Rehovot
ILX
                                                      N/A
Levanon; Avigdor
                        Rehovot
                                            N/A
ILX
                                            N/A
                                                      N/A
Werber; Moshe M.
                         Tel Aviv
ILX
Guy; Rachel
                         Rehovot
                                            N/A
                                                      N/A
ILX
                                            N/A
                                                      N/A
Panet; Amos
                         Jerusalem
ASSIGNEE INFORMATION:
                         CITY
                                            STATE
                                                      ZIP CODE
NAME
COUNTRY
         TYPE CODE
                                                      N/A
Bio-Technology General Iselin
                                            NJ
N/A
         02
Corp.
           8/ 058241
APPL-NO:
DATE FILED: May 4, 1993
PARENT-CASE:
This application is a divisional of U.S. Ser. No. 07/526,397,
filed May 21,
1990, now U.S. Pat. No. 5,270,030; which is a
continuation-in-part of U.S.
Ser. No. 07/345,952, filed Apr. 28, 1989, now abandoned; which
continuation-in-part of U.S. Ser. No. 07/291,951, filed Dec.
29, 1988, now
abandoned.
FOREIGN-APPL-PRIORITY-DATA:
  FOREIGN-PRIORITY:
  FOREIGN-PRIORITY-APPL-NO: CA 2006929
  FOREIGN-PRIORITY-APPL-DATE: December 29, 1989
INT-CL: [6] G01N033/53,A61K051/08 ,C12Q001/56
US-CL-ISSUED: 435/7.21,424/1.69 ,424/9.341 ,424/9.4 ,435/7.8
,435/13 ,436/503
,436/504 ,436/69
US-CL-CURRENT: 435/7.21,424/1.69 ,424/9.341 ,424/9.4 ,435/13
,435/7.8 ,436/503
```

,436/504 ,436/69

FIELD-OF-SEARCH: 435/7.21;435/13;435/7.8;436/503;436/504

;436/69 ;424/9

;424/1.1 ;424/1.69 ;530/380 ;530/381 ;530/350 ;514/2

REF-CITED:

U.S. PATENT DOCUMENTS

PAT-NO ISSUE-DATE PATENTEE-NAME US-CL 4315906 February 1982 Gelder 424/9 5026537 June 1991 Daddiba et al. 424/1.1

FOREIGN PATENT DOCUMENTS

COUNTRY FOREIGN-PAT-NO PUBN-DATE

US-CL

EP 0207751 January 1987

ART-UNIT: 182

PRIMARY-EXAMINER: Saunders; David ASSISTANT-EXAMINER: Grun; James L. ATTY-AGENT-FIRM: White; John P.

ABSTRACT:

This invention provides an imaging agent which comprises a polypeptide

labeled with an imageable marker, such polypeptide having an amino acid

sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin.

The invention further provides a method wherein the imaging agent is used for

imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic

plaque. Further provided are plasmids for expression of polypeptides having an

amino acid sequence substantially present in the fibrin binding domain of

naturally-occurring human fibronectin and being capable of binding to fibrin,

hosts containing these plasmids, methods of producing the polypeptides, methods

of treatment using the polypeptides, and methods of recovering, refolding and

reoxidizing the polypeptides. The invention also provides for purified

polypeptides substantially free of other substances of human origin which have

an amino acid sequence substantially present in the fibrin binding domain of

naturally-occurring human fibronectin and which are capable of binding to fibrin.

8 Claims, 98 Drawing figures

CLAIMS:

What is claimed is:

1. A method for imaging a fibrin-containing substance which comprises

contacting the fibrin-containing substance to be imaged with an imaging agent under conditions such that the imaging agent binds to fibrin in the fibrin-containing substance,

imaging bound imaging agent, and

thereby imaging the fibrin-containing substance,

wherein the imaging agent comprises a polypeptide labeled with an imageable marker,

wherein the polypeptide is a 12 kD polypeptide corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin and comprising the amino acid sequence of amino acids 1-109 as shown in FIG. 1.

- 2. A method of claim 1, wherein the fibrin-containing substance is a thrombus.
- 3. A method of claim 1, wherein the fibrin-containing substance is atherosclerotic plaque.
- 4. The method according to claim 1 wherein the fibrin-containing substance is within blood vessels of a subject and wherein contacting is

performed by administering the imaging agent contained in a suitable carrier to the subject under conditions permitting the imaging agent to enter the blood vessels of the subject.

- 5. A method of claim 4, wherein the fibrin-containing substance is a thrombus.
- 6. A method of claim 4, wherein the fibrin-containing substance is atherosclerotic plaque.
- 7. A method of claim 1, wherein the marker is a radioactive isotope, an element which is opaque to X-rays, or a paramagnetic ion.
- 8. A method of claim 1, wherein the imaging is carried out using a gamma camera.

WEST

Generate Collection

L2: Entry 5 of 5 File: USPT Oct 3, 1995

US-PAT-NO: 5455158

DOCUMENT-IDENTIFIER: US 5455158 A

TITLE: Fibrin binding domain polypeptides and uses and methods of producing same

DATE-ISSUED: October 3, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vogel; Tikva	Rehovot	N/A	N/A	ILX
Levanon; Avigdor	Rehovot	N/A	N/A	ILX
Werber; Moshe M.	Tel Aviv	N/A	N/A	ILX
Guy; Rachel	Rehovot	N/A	N/A	ILX
Panet; Amos	Jerusalem	N/A	N/A	ILX

US-CL-CURRENT: $\underline{435}/\underline{7.21}$; $\underline{424}/\underline{1.69}$, $\underline{424}/\underline{9.341}$, $\underline{424}/\underline{9.4}$, $\underline{435}/\underline{13}$, $\underline{435}/\underline{7.8}$, $\underline{436}/\underline{503}$, $\underline{436}/\underline{504}$, $\underline{436}/\underline{69}$

CLAIMS:

What is claimed is:

1. A method for imaging a fibrin-containing substance which comprises contacting the fibrin-containing substance to be imaged with an imaging agent under conditions such that the imaging agent binds to fibrin in the fibrin-containing substance,

imaging bound imaging agent, and

thereby imaging the fibrin-containing substance,

wherein the imaging agent comprises a polypeptide labeled with an imageable marker, wherein the polypeptide is a 12 kD polypeptide corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin and comprising the amino acid sequence of amino acids 1-109 as shown in FIG. 1.

- 2. A method of claim 1, wherein the fibrin-containing substance is a thrombus.
- 3. A method of claim 1, wherein the fibrin-containing substance is atherosclerotic plaque.
- 4. The method according to claim 1 wherein the fibrin-containing substance is within blood vessels of a subject and wherein contacting is performed by administering the imaging agent contained in a suitable carrier to the subject under conditions permitting the imaging agent to enter the blood vessels of the subject.
- 5. A method of claim 4, wherein the fibrin-containing substance is a thrombus.
- 6. A method of claim 4, wherein the fibrin-containing substance is atherosclerotic plaque.
- 7. A method of claim 1, wherein the marker is a radioactive isotope, an element which is opaque to X-rays, or a paramagnetic ion.
- 8. A method of claim 1, wherein the imaging is carried out using a gamma camera.

Generate Collection

L3: Entry 12 of 12

File: USPT

Dec 14, 1993

US-PAT-NO: 5270030

DOCUMENT-IDENTIFIER: US 5270030 A

TITLE: Fibrin binding domain polypeptide and method of producing

DATE-ISSUED: December 14, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vogel; Tikva	Rehovot	N/A	N/A	ILX
Levanon; Avigdor	Rehovot	N/A	N/A	ILX
Werber; Moshe M.	Tel Aviv	N/A	N/A	ILX
Guy; Rachel	Rehovot	N/A	N/A	ILX
Panet; Amos	Jerusalem	N/A	N/A	ILX

US-CL-CURRENT: $\underline{424}/\underline{1.69}$; $\underline{424}/\underline{9.341}$, $\underline{424}/\underline{9.4}$, $\underline{435}/\underline{252.3}$, $\underline{435}/\underline{252.33}$, $\underline{435}/\underline{320.1}$, $\underline{435}/\underline{69.1}$, $\underline{530}/\underline{350}$, $\underline{530}/\underline{395}$

CLAIMS:

What is claimed is:

- 1. An imaging agent which comprises a polypeptide labeled with an imageable marker, wherein the polypeptide is a 12 kD polypeptide corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin and having the amino acid sequence of amino acids 1-109 as shown in FIG. 1 and being capable of binding to fibrin.
- 2. A composition comprising an effective imaging amount of the imaging agent of claim 1 and a physiologically acceptable carrier.
- 3. An agent of claim 1, wherein the marker is a radioactive isotope, an element which is opaque to X-rays, or a paramagnetic ion.
- 4. An agent of claim 3, wherein the marker is a radioactive isotope.
- 5. An agent of claim 4, wherein the radioactive isotope is indium-111.
- 6. An agent of claim 4, wherein the radioactive isotope is technetium-99m.
- 7. An agent of claim 4, wherein the radioactive isotope is iodine-123, iodine-125, iodine-131, krypton-81m, xenon-133, or gallium-67.
- 8. A purified polypeptide substantially free of other substances of human origin wherein the polypeptide is a 12 kD polypeptide of amino acids 1-109 as shown in FIG. 1 corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin.
- 9. A plasmid for expression of the polypeptide of claim 8 comprising DNA encoding the polypeptide and DNA encoding suitable regulatory elements positioned relative to the DNA encoding the polypeptide so as to effect expression of the polypeptide in a suitable host cell.
- 10. A plasmid according to claim 9 designated pFN 196-2 and deposited in escherichia coli strain A4255 under ATCC Accession No. 63328.
- 11. A cell which comprises the plasmid of claim 9.
- 12. A bacterial cell according to claim 11.
- 13. An Escherichia coli cell according to claim 12.
- 14. An Escherichia coli cell according to claim 13, wherein the plasmid is designated pFN 196-2 and wherein the cell is deposited under ATCC Acession No. 68328.
- 15. A method of producing a 12 kD polypeptide fragment corresponding to an amino acid sequence present in the fibrin binding domain of naturally-occurring human fibronectin which comprises culturing a cell according to claim 11 so that the DNA directs expression of the polypeptide and the cell expressed the polypeptide and recovering from the cell the polypeptide so expressed.